Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity
Journal of Medicinal Chemistry2013Vol. 56(18), pp. 7222–7231
Citations Over TimeTop 10% of 2013 papers
Takayoshi Suzuki, Hiroki Ozasa, Yukihiro Itoh, Peng Zhan, Hideyuki Sawada, Koshiki Mino, Louise J. Walport, Rei Ohkubo, Akane Kawamura, Masato Yonezawa, Yuichi Tsukada, Anthony Tumber, Hidehiko Nakagawa, Makoto Hasegawa, Ryuzo Sasaki, Tamio Mizukami, Christopher J. Schofield, Naoki Miyata
Abstract
Histone N(ε)-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.
Related Papers
- → Arabidopsis REF6 is a histone H3 lysine 27 demethylase(2011)411 cited
- → UTX, a Histone H3-Lysine 27 Demethylase, Acts as a Critical Switch to Activate the Cardiac Developmental Program(2011)253 cited
- → The Histone H3 Lysine 27-Specific Demethylase Jmjd3 Is Required for Neural Commitment(2008)205 cited
- → Epigenetic modifications control the phenotype of alternatively activated macrophages (136.4)(2009)
- → Faculty Opinions recommendation of Arabidopsis REF6 is a histone H3 lysine 27 demethylase.(2011)